EVGNEvogene Ltd.
The Read
9% drop after Q1 2026 results due to cash runway concerns, but can rally about 27% on strategic funding news, showing moves around 15–30% on key catalysts.
The schedule
- Thu15Oct
Nasdaq compliance deadline regarding the $1 minimum bid from $0.35, evaluating a bounce to $0.45 on an extension or a drop to $0.20 on a reverse split announcement.
- Thu10Dec
Year-end update on AgPlenus and Biomica pipelines anchored at $0.30; targets $0.50 on licensing deals aligned with agricultural tailwinds, or $0.20 on delayed progress.
- Wed17Feb
Q3 2026 earnings print assessing subsidiary milestones from a $0.20 anchor, targeting $0.30 on revenue recognition versus $0.15 on sustained cash bleed.
- Sat15May
Q1 2027 results tracking ag-biological sales anchored at $0.30, projecting $0.40 on commercial traction or $0.18 on stagnant revenue.
- Wed19May
Full-year 2026 results and 2027 outlook from $0.20, modeling $0.30 on self-sustaining subsidiary guidance or a $0.12 fallback on continued parent dilution.
Past
- Wed19Aug
Q2 2026 earnings anchored at $0.25, focusing on cash burn reduction, with upside to $0.35 on improved runway or a slide to $0.18 on going-concern risk.
- Wed29Jul
Actual outcome: Bull · $0.61 at outcome
The stock rallied 27%, closely approaching the $0.65 bull target, driven by the announcement of a strategic collaboration with ELEO Inc. to develop next-generation cardiovascular therapies. This partnership validated Evogene's AI-driven computational chemistry platform and provided a non-dilutive catalyst, alleviating immediate funding concerns and driving positive momentum ahead of the company's Q2 earnings release.
Evaluation of Evogene's critical funding path from the $0.41 base, targeting $0.65 on a non-dilutive partnership or risking $0.25 on a toxic parent-level equity raise.
- Wed20May
Actual outcome: Bear · $0.56 at outcome
Evogene reported Q1 2026 financial results, delivering an EPS of -$0.61 that met analyst estimates. However, the stock fell 22.9% and broke well below the $0.65 bear floor, as the results failed to alleviate investor concerns regarding the company's cash burn and overall cash runway. The ongoing pressure on the stock reflects market skepticism about Evogene's ability to stabilize revenue and control costs.
Q1 2026 results and commentary on Evogene's cash runway, subsidiary performance, and cost structure, with investors focused on whether revenue stabilizes and cash burn is controlled at a $0.82 share price.
